Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 7.83TCr 6.77TCr 6.33TCr 5.8TCr 11TCr 7,45400Cr 11TCr 74TCr 29TCr 3,73600Cr 29TCr 29TCr 12,35200Cr P/E 2026 *
18.5x
P/E 2027 * 15.6x
Enterprise Value 7.15TCr 6.18TCr 5.77TCr 5.29TCr 9.96TCr 6,80000Cr 10TCr 68TCr 27TCr 3,40900Cr 27TCr 26TCr 11,26800Cr EV / Sales 2026 *
4.23x
EV / Sales 2027 * 3.7x
Free-Float
71.07%
Yield 2026 *
0.5%
Yield 2027 * 0.57%
1 day+1.59%
1 week+6.23%
Current month+2.85%
1 month+20.71%
3 months+8.78%
6 months-0.15%
Current year+1.62%
1 week 747
Extreme 747
785.99
1 month 637.8
Extreme 637.8
785.99
Current year 591.52
Extreme 591.52
821.11
1 year 541
Extreme 541
821.11
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 01/01/2001
Chief Executive Officer 73 08/01/1988
Director of Finance/CFO 55 05/02/2024
Director TitleAgeSince
Chairman 73 09/06/2023
Director/Board Member 85 01/06/1991
Director/Board Member 85 01/06/1991
Date Insider Type Main position Quantity % Market Cap.
02/07/26 Sell

Director

-200 0.0002%
19/02/26 Fiscal year

Director

4,914 0.0048%
09/02/26 Fiscal year

SVP Controller

4,036 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
+1.59%+6.23%+41.29%+2.34% 7.71TCr
-0.84%+2.81%+22.05%+180.42% 4.94TCr
+2.77%+1.90%-1.84%+27.14% 4.93TCr
-0.13%+3.33%-50.97%-50.14% 4.46TCr
+0.80%+0.00%+60.77%-22.68% 3.05TCr
+1.84%-1.98%+55.26%+89.47% 2.4TCr
+9.86%+2.16%+121.53%-45.31% 2.15TCr
+4.29%+7.66%-3.26%+189.18% 2.02TCr
+1.66%-4.10%+68.10%+124.13% 1.63TCr
+2.03%+2.85%+88.53%+170.34% 1.62TCr
Average +2.39%+0.79%+40.15%+66.49% 3.49TCr
Weighted average by Cap. +1.83%+2.49%+29.16%+49.51%

Financials

2026 *2027 *
Net sales 1.69TCr 1.46TCr 1.36TCr 1.25TCr 2.35TCr 1,60700Cr 2.39TCr 16TCr 6.28TCr 81TCr 6.34TCr 6.2TCr 2,66300Cr 1.83TCr 1.59TCr 1.48TCr 1.36TCr 2.56TCr 1,74500Cr 2.6TCr 17TCr 6.82TCr 87TCr 6.89TCr 6.74TCr 2,89200Cr
Net income 460.64Cr 398.45Cr 372.09Cr 341.34Cr 642.02Cr 44TCr 652.21Cr 4.37TCr 1.71TCr 22TCr 1.73TCr 1.69TCr 73TCr 535.26Cr 463Cr 432.37Cr 396.64Cr 746.02Cr 51TCr 757.87Cr 5.07TCr 1.99TCr 26TCr 2.01TCr 1.97TCr 84TCr
Net Debt -686.84Cr -594.11Cr -554.81Cr -508.96Cr -957.29Cr -65TCr -972.49Cr -6.51TCr -2.55TCr -33TCr -2.58TCr -2.52TCr -1,08300Cr -1.06TCr -912.91Cr -852.52Cr -782.06Cr -1.47TCr -1,00400Cr -1.49TCr -10TCr -3.93TCr -50TCr -3.96TCr -3.88TCr -1,66400Cr
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,410
Date Price Change Volume
07/26/07 $784.36 +1.59% 7,16,725
06/26/06 $772.11 +0.46% 7,83,950
05/26/05 $768.58 +1.04% 5,32,482
04/26/04 $760.66 +0.19% 8,17,280
03/26/03 $759.24 -0.44% 8,42,730
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
784.36USD
Average target price
833.54USD
Spread / Average Target
+6.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REGN Stock